GLG News by Nursing Home & Skilled Nursing Facility Experts

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Rx Savings with Generic vs Branded Medications

March 28, 2011

Analysis of:Buying Brand-Name Drugs Over Generics Raises Medicaid Costs | www.bloomberg.com

With dollar shortfalls for Rx benefits, controlling drug costs is imperative. By utilizing a strict formulary of covered products, along with clear, real time messaging to the pharmacies,  the generic fill rate (GFR) will rise. With a higher GFR, savings is attained.

David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.

CVS vs. Walgreen's and the latest....

June 12, 2010

As a consultant and clinical pharmacist with over 30 years experience, I am glad someone.... and in this case... Walgreen's finally woke up to fees that are insulting low and a losing proposition. It has been well established the the "average expense to dispense a prescription" (the pharmacy's actual costs including rent, payroll, overhead, etc) is in the $10 range per prescription. Why would any pharmacy sign a contract with a fee of $1.50 per prescription?

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Lupin's opportunity to drop the Lotrel margin!

February 15, 2010

Analysis of:Lupin gets US FDA approval for hypertension capsules | www.pharmabiz.com

The approval of Lupin's generic Lotrel line will create one more player in a field that is currently not very crowded. Yet, don't expect the other players to not react! Generic Lotrel is currently priced relatively high compared to other multi-source hypertensive products.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Cetirizine OTC liquid. A day late and a dollar short.

February 8, 2010

Analysis of:Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

Why the delay? Teva, Taro, and Perrigo all have strong footholds in this market. Rx and OTC competition remains strong, thus what would allow a new player to grow quickly outside of eroding the price market?

Jon StrasserAssistant Professor of Radiation OncologyTHOMAS JEFFERSON UNIVERSITY

Particle Beam Technology - Costly and a limited utility

October 26, 2009

Analysis of:Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Starpharma gets US patent for use of VivaGel for protection against STIs

September 29, 2009

Analysis of:Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com

Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Stelara new Option for Psoriasis

September 26, 2009

Analysis of:Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com

The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.

Glen McDanielPresident and Chief Executive OfficerGM Global

Roche adds to anti-MRSA arsenal in Europe

April 8, 2009

Analysis of:Roche introduces new LightCycler MRSA advanced test in EU | www.roche.com

European healthcare organizations have always been more aggressive in identifying MRSA infections. Europe popularized the "search and destroy" protocol of MRSA containment. This new method by Roche is a valuable addition in this arsenal. I expect the LightCycler MRSA Test by Roche to be popular and very lucrative for Roche.

David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.

Tamper Proof Narcotic Pain pill? YES

November 13, 2008

Analysis of:FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com

This drug will allow patients in severe pain to get the necessary pain relief and not have to worry about the other patients that abuse the drug.

Glen McDanielPresident and Chief Executive OfficerGM Global

Boomers numbers and demands point to increased demand for medical real estate

July 1, 2008

Analysis of:Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals | www.bio-medicine.org

Baby boomers are rapidly aging. According to Census Bureau by 2010 there will be 77 million people aged 55 and older; a number which will grow to a whopping 98 million by 2020. This aging population, living longer with chronic illnesses and more demanding of cafeteria-type service will drive the demand for medical services and more medical real estate into the forseeable future.

Page : 12345678910Next1 to 10 of 152